Immunogenicity of novel recombinant human activated factor VII analogues on factor VII neonatally-tolerized rats

Thrombosis and Haemostasis

Volumn 98, Issue 4, 2007, Pages 721-725

  Sommer, Christian ^a   Jørgensen, Peer Norbert ^a   Salanti, Zaki ^b   Clausen, Jes Thorn ^a   Jensen, Lisbeth Bjerring ^a  

^a NOVO NORDISK A S   (Denmark)

^b LAB Research Denmark   (Denmark)

Author keywords

Immunogenicity; Neonatal rat model; rFVlla; rFVlla analogues; Tolerance

Indexed keywords

BLOOD CLOTTING FACTOR; FREUND ADJUVANT; OVALBUMIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 7A DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; NEWBORN; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; ANIMALS, NEWBORN; BINDING SITES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIIA; FREUND'S ADJUVANT; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 35048847414     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-05-0349     Document Type: Article

References (22)

1. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
2. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59: 8-15.
3. Grounds RM, Bolan C. Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings. Crit Care 2005; 9 (Suppl 5): S29-S36.
4. Diprose P, Herbertson MJ, O'Shaughnessy D, et al. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005; 95: 596-602.
5. Planinsic RM, van der Meer J, Testa G, et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005; 11: 895-900.
6. Lodge JP, Jonas S, Jones RM, et al; rFVIIa OLT Study Group. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11: 973-979.
7. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201-205.
8. Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth 2005; 94: 592-595.
9. O'Connell NM, Perry DJ, Hodgson AJ, et al. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion 2003; 43: 1711-1716.
10. Monroe DM, Hoffman M, Oliver JA, et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-547.
11. Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci USA 2001; 98: 13583-13588.
12. Tranholm M, Kristensen K, Kristensen AT, et al. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 2003; 102; 3615-3620.
13. Ghosh S, Ezban M, Persson E, et al. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J Thromb Haemost 2007; 5: 336-346.
14. Allen GA, Persson E, Campbell RA, et al. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007; 27: 683-689.
15. Lisman T, de Groot PG, Lambert T, et al. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A. J Thromb Haemost 2003; 1: 2175-2178.
16. Nicolaisen EM. Long-term follow-up with regard to potential immunogenicity: Clinical experience with NovoSevene® (recombinant factor VIIa). Haemostasis 1996; 26 (Suppl 1): 98-101.
17. Pittman DD, Alderman EM, Tomkinson KN, et al. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993; 81: 2925-2935.
18. Nicolaisen EM, Kristensen H, Kristensen A, et al. Evaluation of potential antigenicity of active-site-inhibited recombinant human FVIIa (FFR-rFVIIa) in an immune-tolerant rat model. Thromb Haemost 2002; 87: 836-839.
19. ICH Harmonised Tripartite Guideline: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6 (Ref. CPMP/ICH/302/95). ICH 1997. http://www.ich.org/LOB/Media/MEDIA503.pff
20. Committee for Medicinal Products for Human Use. Concept Paper on Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins (Ref. EMEA/CHMP/BMWP/246511/2005). EMEA 2007. http://www.emea.europa.eu/pdfs/human/biosimilar/24651105en.pdf
21. Persson E, Bak H, Olsen OH. Substitution of valine for leucine 305 in factor VIIa increases the intrinsic amidolytic activity. J Biol Chem 2001; 276: 29195-29199.
22. Lev EI, Marmur JD, Zdravkovic M, et al. Anti-thrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study. Anterioscler Thromb Vasc Biol 2002; 22: 1036-1041.